PLSE
$22.32
Pulse Biosciences, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft ...
Recent News
Is Pulse Biosciences’ (PLSE) Thyroid Cancer Feasibility Study a Prelude to a Broader Platform Strategy?
Pulse Biosciences recently reported first patient treatments in a multi-center, first-in-human feasibility study of its FDA-cleared nPulse Vybrance Percutaneous Electrode System using nanosecond pulsed field ablation to treat small papillary thyroid microcarcinoma tumors under 1.5 cm at sites in Florida and Texas. This move extends Vybrance’s use from benign thyroid nodules into a cancer indication under an Investigational Device Exemption, potentially broadening its clinical and commercial...
A Look At Pulse Biosciences (PLSE) Valuation As Thyroid Cancer Feasibility Study Begins
Pulse Biosciences (PLSE) shares are in focus after the company reported first patient enrollments and initial treatments in a multicenter feasibility study of its nsPFA based Vybrance system for early stage papillary thyroid cancer. See our latest analysis for Pulse Biosciences. The Vybrance thyroid cancer study comes after a series of recent thyroid focused updates and conference presentations, with the 7 day share price return of 18.16% and 90 day share price return of 51.58% suggesting...
Is Pulse Biosciences (PLSE) Pricing Make Sense After Recent Volatility And Cash Flow Forecasts?
If you are wondering whether Pulse Biosciences at around US$18.73 still lines up with its fundamentals, you are not alone. This article will walk through what that price might really represent for you as a shareholder or potential investor. The stock has been volatile recently, with a 12.6% decline over the last 7 days, a 35.4% return over the last 30 days, a 39.9% return year to date, a 2.3% return over the last year, a very large 3 year return, and a 27.1% decline over 5 years. These moves...
Pulse Biosciences, Inc. Q4 2025 Earnings Call Summary
Moby summary of Pulse Biosciences, Inc.'s Q4 2025 earnings call
Pulse Biosciences Inc (PLSE) Q4 2025 Earnings Call Highlights: Innovations and Challenges in Focus
Pulse Biosciences Inc (PLSE) showcases groundbreaking advancements and strategic hurdles as it navigates financial and regulatory landscapes.